We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Exelixis, Inc. is placed eighth among the best cancer ...
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Zacks Investment Research on MSN
Will Exelixis (EXEL) beat estimates again in its next earnings report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other ...
Exelixis, Inc. EXEL shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in advanced neuroendocrine tumors.
Exelixis, Inc. (NASDAQ:EXEL) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 24, Stephens upgraded the company’s stock to “Overweight” from “Equal Weight” with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback